2022 World Conference on Lung Cancer (ePosters)-EP11.01-004. An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer

Pdf Summary

A study was conducted to evaluate the clinical utility of reflex-ordered molecular testing in non-small cell lung cancer (NSCLC). The study analyzed consecutive cases of NSCLC between November 2020 and January 2022. A two-step reflex test was implemented at the time of pathological diagnosis to screen for 10 biomarkers including EGFR, KRAS, BRAF, ERBB2, ALK, ROS1, PD-L1, RET, MET, and NTRK. The aim was to improve the molecular diagnostic workup and enable personalized therapy for NSCLC patients.<br /><br />The results of the study showed that the two-step reflex testing approach was effective, with low failure rates and short turnaround times. The prevalence and types of genetic alterations detected were consistent with literature data. The biomarkers detected varied in frequency, with the most common being KRAS G12C, followed by EGFR and KRAS. Notably, the study identified one case of ROS1 rearrangement and three cases of ERBB2 alterations.<br /><br />The study also found that PD-L1 testing was done in the majority of cases and was determined to be adequate. The failure rate for the first-level reflex test was low at 1.2%, while the failure rate for the second-level reflex test was higher at 8.3%. Additionally, a small percentage of patients underwent rebiopsy for biomarker testing.<br /><br />The time from diagnosis to the first-level reflex test, including PD-L1 testing, was a median of 8 days, while the time to the second-level reflex test was a median of 16.5 days. These findings suggest that implementing a standardized comprehensive strategy for molecular testing in NSCLC can increase timely opportunities for personalized therapy.<br /><br />Overall, the study demonstrates the effectiveness and feasibility of a two-step reflex testing approach for multiple biomarker analysis in NSCLC. The results highlight the importance of molecular testing in guiding treatment decisions for NSCLC patients.

Asset Subtitle

Giacomo Pelizzari

Meta Tag

Speaker Giacomo Pelizzari

Topic Pathology - Genomics & Analytics

Keywords

clinical utility

molecular testing

NSCLC

biomarkers

EGFR

KRAS

PD-L1

genetic alterations

personalized therapy

timely opportunities